The experimental oral therapy VQ-101 can successfully restore a critical cellular function in people with a genetic form of Parkinson’s disease, the treatment’s developer, Vanqua Bio, has announced. One month of daily treatment with VQ-101 safely and robustly boosted the activity of the glucocerebrosidase (GCase) enzyme in patients…
Neurosurgeons temporarily implanted a tiny device into the brains of three people with Parkinson’s disease to collect data on a poorly known brain region, with the goal of understanding how Parkinson’s affects executive function. Doctors at the University of Colorado Anschutz — the first site authorized by the U.S.
Pharmather is planning to meet with the U.S. Food and Drug Administration (FDA) in hopes of reaching an agreement on the design of a future Phase 3 clinical trial testing its generic ketamine product Ketarx in individuals with Parkinson’s disease. The plans were mentioned in a company…
People diagnosed with Parkinson’s disease in their 80s were significantly more likely to show evidence of brain buildup of amyloid-beta, a protein linked to cognitive decline in Alzheimer’s disease, than those diagnosed at a younger age, a study found. Neither group showed signs of cognitive impairment. The researchers…
An international team of scientists has identified imaging biomarkers that can predict which people with REM sleep behavior disorder (RBD) will develop Parkinson’s disease, or who might progress to dementia with Lewy bodies (DLB). Most individuals with RBD — a sleep disorder in which people unknowingly act out…
Parkinson’s disease patients in a clinical trial preferred Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) technology — which automatically adjusts stimulation in response to brain signals — to traditional continuous DBS therapy. The ADAPT-PD (NCT04547712) study also found that BrainSense was safe and effective, and that it…
Oncodesign Precision Medicine (OPM) joined a Michael J. Fox Foundation (MJFF) program to develop potential therapies that target the LRRK2 protein, a key contributor to some forms of Parkinson’s disease. “Our mission has always been to put patients at the center of our innovation,” Jan Hoflack, PhD, OPM’s…
Abbvie has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of tavapadon as a Parkinson’s disease treatment. Clinical data have shown that the once-daily oral small molecule appears safe, reduces motor symptoms, and prolongs periods when these symptoms are well managed. The application is…
In a trial milestone, participants in the third patient group of the ASPIRO Phase 1/2a study (NCT06344026) are now receiving the commercial formulation of ANPD001, Aspen Neuroscience’s cell therapy candidate for Parkinson’s disease. While participants in earlier groups also received ANPD001, the third group is the…
The first European patients in Askbio‘s Phase 2 clinical trial of AB-1005, an experimental gene therapy for Parkinson’s disease, have been randomly assigned to treatment groups. The study, REGENERATE-PD (NCT06285643), has begun randomizing participants at sites in Poland and the U.K. Trial sites in Germany are…
Get regular updates to your inbox.
